Longer term follow‐up is needed to investigate clinical outcomes in patients with a history of COVID‐19 treated with RASi—previous studies in patients without COVID‐19 demonstrated that angiotensin‐converting enzyme inhibition or ARB‐based treatment is associated with lower mortality in the follow‐up after AKI.58 Here, ACE is linked to acute kidney injury.